Story Timeline
Who reported a story first, and how coverage spread across the spectrum.
Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial
1 articles over 1 hours.
First rightSouth China Morning Postfirst overall
- South China Morning PostLeans rightChinese drug iza-bren doubles lung cancer survival window in phase 3 trial
How this was worked out
Every article INDB grouped into this story, in the order the outlets published them (times in UTC, from the outlets' feeds).
How INDB scores stories · Data: stories INDB grouped from the outlets on the sources page.